Pneumococcus

Medical Clinics of North America

Volumn 97, Issue 4, 2013, Pages 647-666

  Ash, Samuel Y ^a   Sheffield, John V L ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Antibiotic resistance; Bacterial illnesses; Bacterial pneumonia; Immunization; Invasive pneumococcal disease; Pneumococcus; Streptococcus pneumoniae; Treatment

Indexed keywords

BETA LACTAM; DOXYCYCLINE; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PNEUMOCOCCUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ASPLENIA; BACTEREMIA; BACTERIAL ARTHRITIS; BRAIN ABSCESS; COMMUNITY ACQUIRED PNEUMONIA; ENDOCARDITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INCIDENCE; INFECTION RATE; INFECTION RISK; MORTALITY; NONHUMAN; OSTEOMYELITIS; OTITIS MEDIA; PATHOGENESIS; PERICARDITIS; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; RISK FACTORS; UNITED STATES; WORLD HEALTH;

EID: 84879782389     PISSN: 00257125     EISSN: 15579859     Source Type: Journal    
DOI: 10.1016/j.mcna.2013.03.005     Document Type: Review

References (110)

1. Musher D.M. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis 1992, 14(4):801-807.
2. Burman L.A., Norrby R., Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis 1985, 7(2):133-142.
3. CDC - ABCs: 2010 Streptococcus pneumoniae surveillance report - active bacterial core surveillance. Available at: Accessed November 4, 2012. http://www.cdc.gov/abcs/reports-findings/survreports/spneu10.html.
4. Dowling J.N., Sheehe P.R., Feldman H.A. Pharyngeal pneumococcal acquisitions in "normal" families: a longitudinal study. JInfect Dis 1971, 124(1):9-17.
5. Hendley J.O., Sande M.A., Stewart P.M., et al. Spread of Streptococcus pneumoniae in families. I. Carriage rates and distribution of types. JInfect Dis 1975, 132(1):55-61.
6. Austrian R. Some observations on the pneumococcus and on the current status of pneumococcal disease and its prevention. Rev Infect Dis 1981, 3(Suppl):S1-S17.
7. Broome C.V., Facklam R.R. Epidemiology of clinically significant isolates of Streptococcus pneumoniae in the United States. Rev Infect Dis 1981, 3(2):277-281.
8. Hoge C.W., Reichler M.R., Dominguez E.A., et al. An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. NEngl J Med 1994, 331(10):643-648.
9. CDC - Surveillance of pneumococcal - Chapter 11-Vaccine preventable diseases. Available at: Accessed November 14, 2012. http://www.cdc.gov/vaccines/pubs/surv-manual/chpt11-pneumo.html.
10. Janoff E.N., Rubins J.B. Invasive pneumococcal disease in the immunocompromised host. Microb Drug Resist 1997, 3(3):215-232.
11. Lipsky B.A., Boyko E.J., Inui T.S., et al. Risk factors for acquiring pneumococcal infections. Arch Intern Med 1986, 146(11):2179-2185.
12. Janoff E.N., Breiman R.F., Daley C.L., et al. Pneumococcal disease during HIV infection. Epidemiologic, clinical, and immunologic perspectives. Ann Intern Med 1992, 117(4):314-324.
13. Redd S.C., Rutherford G.W., Sande M.A., et al. The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. JInfect Dis 1990, 162(5):1012-1017.
14. Marrie T.J. Pneumococcal pneumonia: epidemiology and clinical features. Semin Respir Infect 1999, 14(3):227-236.
15. Tuomanen E.I., Austrian R., Masure H.R. Pathogenesis of pneumococcal infection. NEngl J Med 1995, 332(19):1280-1284.
16. Knecht J.C., Schiffman G., Austrian R. Some biological properties of pneumococcus type 37 and the chemistry of its capsular polysaccharide. JExp Med 1970, 132(3):475-487.
17. Austrian R. Some aspects of the pneumococcal carrier state. JAntimicrob Chemother 1986, 18(Suppl A):35-45.
18. Hakenbeck R., Briese T., Chalkley L., et al. Antigenic variation of penicillin-binding proteins from penicillin-resistant clinical strains of Streptococcus pneumoniae. JInfect Dis 1991, 164(2):313-319.
19. Boulnois G.J., Paton J.C., Mitchell T.J., et al. Structure and function of pneumolysin, the multifunctional, thiol-activated toxin of Streptococcus pneumoniae. Mol Microbiol 1991, 5(11):2611-2616.
20. Trampuz A., Widmer A.F., Fluckiger U., et al. Changes in the epidemiology of pneumococcal bacteremia in a Swiss university hospital during a 15-year period, 1986-2000. Mayo Clin Proc 2004, 79(5):604-612.
21. Cundell D.R., Weiser J.N., Shen J., et al. Relationship between colonial morphology and adherence of Streptococcus pneumoniae. Infect Immun 1995, 63(3):757-761.
22. Håkansson A., Kidd A., Wadell G., et al. Adenovirus infection enhances invitro adherence of Streptococcus pneumoniae. Infect Immun 1994, 62(7):2707-2714.
23. Ginsberg J., Mohebbi M.H., Patel R.S., et al. Detecting influenza epidemics using search engine query data. Nature 2009, 457(7232):1012-1014.
24. Bartlett J.G., Mundy L.M. Community-acquired pneumonia. NEngl J Med 1995, 333(24):1618-1624.
25. Fang G.D., Fine M., Orloff J., et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990, 69(5):307-316.
26. Bochud P.Y., Moser F., Erard P., et al. Community-acquired pneumonia. A prospective outpatient study. Medicine (Baltimore) 2001, 80(2):75-87.
27. File T.M. Community-acquired pneumonia. Lancet 2003, 362(9400):1991-2001.
28. Heffron R. Pneumonia: with special reference to pneumococcus lobar pneumonia 1979, Harvard University Press, Cambridge (MA).
29. del Rio C., McGowan J.E. Severe diarrhea in pneumococcal bacteremia: croupous colitis. JAMA 1987, 257(2):189.
30. Kantor H.G. The many radiologic facies of pneumococcal pneumonia. AJR Am J Roentgenol 1981, 137(6):1213-1220.
31. Ort S., Ryan J.L., Barden G., et al. Pneumococcal pneumonia in hospitalized patients. Clinical and radiological presentations. JAMA 1983, 249(2):214-218.
32. Leatherman J.W., Iber C., Davies S.F. Cavitation in bacteremic pneumococcal pneumonia. Causal role of mixed infection with anaerobic bacteria. Am Rev Respir Dis 1984, 129(2):317-321.
33. Isaacs R.D. Necrotizing pneumonia in bacteraemic pneumococcal infection. Br J Dis Chest 1986, 80(3):295-296.
34. Rein M., Gwaltney J., O'Brien W., et al. Accuracy of Gram's stain in identifying pneumococci in sputum. JAMA 1978, 239(25):2671-2673.
35. Marrie T.J. Community-acquired pneumonia. Clin Infect Dis 1994, 18(4):501-513. [quiz: 514-5].
36. García-Vázquez E., Marcos M.A., Mensa J., et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004, 164(16):1807-1811.
37. Musher D.M., Montoya R., Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004, 39(2):165-169.
38. Lentino J.R., Lucks D.A. Nonvalue of sputum culture in the management of lower respiratory tract infections. JClin Microbiol 1987, 25(5):758-762.
39. Barrett-Connor E. The nonvalue of sputum culture in the diagnosis of pneumococcal pneumonia. Am Rev Respir Dis 1971, 103(6):845-848.
40. Mandell L.A., Wunderink R.G., Anzueto A., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007, 44(Suppl 2):S27-S72.
41. Sordé R., Falcó V., Lowak M., et al. Current and potential usefulness of pneumococcal urinary antigen detection in hospitalized patients with community-acquired pneumonia to guide antimicrobial therapy. Arch Intern Med 2011, 171(2):166-172.
42. Dowell S.F., Garman R.L., Liu G., et al. Evaluation of Binax NOW, an assay for the detection of pneumococcal antigen in urine samples, performed among pediatric patients. Clin Infect Dis 2001, 32(5):824-825.
43. Tilghman R., Finland M. Clinical significance of bacteremia in pneumococcic pneumonia. Arch Intern Med 1937, 59(4):602-619.
44. Hook E.W., Horton C.A., Schaberg D.R. Failure of intensive care unit support to influence mortality from pneumococcal bacteremia. JAMA 1983, 249(8):1055-1057.
45. Austrian R., Gold J. Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 1964, 60:759-776.
46. Ortqvist A., Grepe A., Julander I., et al. Bacteremic pneumococcal pneumonia in Sweden: clinical course and outcome and comparison with non-bacteremic pneumococcal and mycoplasmal pneumonias. Scand J Infect Dis 1988, 20(2):163-171.
47. Sheffield J.V., Chu L., Root R. Pneumococcal bacteremia a Harborview Medical Center: impact of intensive care unit support 1997, Clinical Infectious Diseases, New Orleans (LA), p. 438.
48. Taylor S.N., Sanders C.V. Unusual manifestations of invasive pneumococcal infection. Am J Med 1999, 107(1A):12S-27S.
49. Eskola J., Kilpi T., Palmu A., et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. NEngl J Med 2001, 344(6):403-409.
50. Vardakas K.Z., Matthaiou D.K., Falagas M.E. Adjunctive dexamethasone therapy for bacterial meningitis in adults: a meta-analysis of randomized controlled trials. Eur J Neurol 2009, 16(6):662-673.
51. de Gans J., van de Beek D. Dexamethasone in adults with bacterial meningitis. NEngl J Med 2002, 347(20):1549-1556.
52. Tunkel A.R., Hartman B.J., Kaplan S.L., et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004, 39(9):1267-1284.
53. Cunha B.A. Clinical relevance of penicillin-resistant Streptococcus pneumoniae. Semin Respir Infect 2002, 17(3):204-214.
54. Coyle P.K. Glucocorticoids in central nervous system bacterial infection. Arch Neurol 1999, 56(7):796-801.
55. Viladrich P.F., Gudiol F., Liñares J., et al. Evaluation of vancomycin for therapy of adult pneumococcal meningitis. Antimicrob Agents Chemother 1991, 35(12):2467-2472.
56. Sapolsky R.M., Pulsinelli W.A. Glucocorticoids potentiate ischemic injury to neurons: therapeutic implications. Science 1985, 229(4720):1397-1400.
57. Jernigan D.B., Cetron M.S., Breiman R.F. Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP). A strategy from the DRSP Working Group. JAMA 1996, 275(3):206-209.
58. Gold H.S., Moellering R.C. Antimicrobial-drug resistance. NEngl J Med 1996, 335(19):1445-1453.
59. Whitney C.G., Farley M.M., Hadler J., et al. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. NEngl J Med 2000, 343(26):1917-1924.
60. Doern G.V., Brueggemann A.B., Huynh H., et al. Antimicrobial resistance with Streptococcus pneumoniae in the United States, 1997 98. Emerg Infect Dis 1999, 5(6):757-765.
61. Jenkins S.G., Brown S.D., Farrell D.J. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008, 7:1.
62. Mera R.M., Miller L.A., Amrine-Madsen H., et al. Impact of new Clinical Laboratory Standards Institute Streptococcus pneumoniae penicillin susceptibility testing breakpoints on reported resistance changes over time. Microb Drug Resist 2011, 17(1):47-52.
63. Jones R.N., Sader H.S., Mendes R.E., et al. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis 2013, 75(1):107-109.
64. Friedland I.R., McCracken G.H. Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. NEngl J Med 1994, 331(6):377-382.
65. Takata G.S., Chan L.S., Shekelle P., et al. Evidence assessment of management of acute otitis media: I. The role of antibiotics in treatment of uncomplicated acute otitis media. Pediatrics 2001, 108(2):239-247.
66. Pallares R., Gudiol F., Liñares J., et al. Risk factors and response to antibiotic therapy in adults with bacteremic pneumonia caused by penicillin-resistant pneumococci. NEngl J Med 1987, 317(1):18-22.
67. Feldman C., Kallenbach J.M., Miller S.D., et al. Community-acquired pneumonia due to penicillin-resistant pneumococci. NEngl J Med 1985, 313(10):615-617.
68. Tleyjeh I.M., Tlaygeh H.M., Hejal R., et al. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2006, 42(6):788-797.
69. Rivera A.M., Boucher H.W. Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci. Mayo Clin Proc 2011, 86(12):1230-1243.
70. Hyde T.B., Gay K., Stephens D.S., et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001, 286(15):1857-1862.
71. Kim S.H., Song J.H., Chung D.R., et al. Changing trends in antimicrobial resistance and serotypes of streptococcus pneumoniae isolates in Asian Countries: an Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Antimicrob Agents Chemother 2012, 56(3):1418-1426.
72. Pérez-Trallero E., García-de-la-Fuente C., García-Rey C., et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005, 49(5):1965-1972.
73. Musher D.M., Dowell M.E., Shortridge V.D., et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. NEngl J Med 2002, 346(8):630-631.
74. Kelley M.A., Weber D.J., Gilligan P., et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000, 31(4):1008-1011.
75. Lonks J.R., Garau J., Gomez L., et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002, 35(5):556-564.
76. Chen D.K., McGeer A., de Azavedo J.C., et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. NEngl J Med 1999, 341(4):233-239.
77. Fuller J.D., Low D.E. Areview of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis 2005, 41(1):118-121.
78. Davidson R., Cavalcanti R., Brunton J.L., et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. NEngl J Med 2002, 346(10):747-750.
79. Anderson K.B., Tan J.S., File T.M., et al. Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003, 37(3):376-381.
80. Ho P.L., Tse W.S., Tsang K.W., et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001, 32(5):701-707.
81. Ho P.L., Yung R.W., Tsang D.N., et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. JAntimicrob Chemother 2001, 48(5):659-665.
82. Yu V.L., Chiou C.C., Feldman C., et al. An international prospective study of pneumococcal bacteremia: correlation with invitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003, 37(2):230-237.
83. Ruhe J.J., Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis 2003, 36(9):1132-1138.
84. Campbell G.D., Silberman R. Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 1998, 26(5):1188-1195.
85. Clavo-Sánchez A.J., Girón-González J.A., López-Prieto D., et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997, 24(6):1052-1059.
86. Vanderkooi O.G., Low D.E., Green K., et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005, 40(9):1288-1297.
87. Reinert R.R., Jacobs M.R., Appelbaum P.C., et al. Relationship between the Original Multiply Resistant South African Isolates of Streptococcus pneumoniae from 1977 to 1978 and Contemporary International Resistant Clones. JClin Microbiol 2005, 43(12):6035-6041.
88. San Pedro G.S., Cammarata S.K., Oliphant T.H., et al. Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002, 34(10):720-728.
89. Fritsche T.R., Sader H.S., Stilwell M.G., et al. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 2005, 52(3):187-193.
90. File T.M., Low D.E., Eckburg P.B., et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis 2010, 51(12):1395-1405.
91. Saravolatz L.D., Stein G.E., Johnson L.B. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2011, 52(9):1156-1163.
92. Robinson K.A., Baughman W., Rothrock G., et al. Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: opportunities for prevention in the conjugate vaccine era. JAMA 2001, 285(13):1729-1735.
93. Hirst C., Owusu-Ofori S. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease. Cochrane Database Syst Rev 2012, (9). CD003427.
94. Austrian R., Douglas R.M., Schiffman G., et al. Prevention of pneumococcal pneumonia by vaccination. Trans Assoc Am Physicians 1976, 89:184-194.
95. CDC - Pinkbook: pneumococcal disease chapter - epidemiology of vaccine-preventable diseases. Available at: Accessed November 14, 2012. http://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html.
96. van der Poll T., Opal S.M. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009, 374(9700):1543-1556.
97. Plouffe J.F., Breiman R.F., Facklam R.R. Bacteremia with Streptococcus pneumoniae. Implications for therapy and prevention. Franklin County Pneumonia Study Group. JAMA 1996, 275(3):194-198.
98. Broome C.V., Facklam R.R., Allen J.R., et al. From the center for disease control. Epidemiology of pneumococcal serotypes in the United States, 1978-1979. JInfect Dis 1980, 141(1):119-123.
99. Jackson L.A., Neuzil K.M., Yu O., et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. NEngl J Med 2003, 348(18):1747-1755.
100. Vila-Corcoles A., Salsench E., Rodriguez-Blanco T., et al. Clinical effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia in middle-aged and older adults: a matched case-control study. Vaccine 2009, 27(10):1504-1510.
101. Fine M.J., Smith M.A., Carson C.A., et al. Efficacy of pneumococcal vaccination in adults. A meta-analysis of randomized controlled trials. Arch Intern Med 1994, 154(23):2666-2677.
102. Centers for Disease Control and Prevention (CDC) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2012, 61:816-819.
103. Whitney C.G., Farley M.M., Hadler J., et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. NEngl J Med 2003, 348(18):1737-1746.
104. Centers for Disease Control and Prevention (CDC) Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction-eight states, 1998-2005. MMWR Morb Mortal Wkly Rep 2008, 57(6):144-148.
105. Hsu H.E., Shutt K.A., Moore M.R., et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. NEngl J Med 2009, 360(3):244-256.
106. Huss A., Scott P., Stuck A.E., et al. Efficacy of pneumococcal vaccination in adults: a meta-analysis. CMAJ 2009, 180(1):48-58.
107. Musher D.M. Pneumococcal vaccine-direct and indirect ("herd") effects. NEngl J Med 2006, 354(14):1522-1524.
108. Flannery B., Heffernan R.T., Harrison L.H., et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006, 144(1):1-9.
109. Pichichero M.E., Casey J.R. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA 2007, 298(15):1772-1778.
110. Hampton L.M., Farley M.M., Schaffner W., et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. JInfect Dis 2012, 205(3):401-411.